Shanghai Lekuang Huilin Pharmaceutical Technology

Shanghai Lekuang Huilin Pharmaceutical Technology Co., Ltd. (also known as Lekuang Huilin or Lagom Pharma) is a Chinese pharmaceutical company focused on the development, commercialization, and academic promotion of innovative and complex generic drugs. In July 2025, the company entered into a major domestic licensing agreement with Beijing Sun-Novo Pharmaceutical Research (and its subsidiary Chengdu Nuohe Shengtai) to co-develop STC007, a novel small-molecule kappa opioid receptor (KOR) agonist, for postoperative pain management in mainland China. Under the terms of the agreement, Lekuang Huilin acquired a 20% interest in the project for a total milestone-based payment of 200 million RMB ($28 million USD), including an upfront payment of 100 million RMB ($14 million USD). The lead asset, STC007, is currently in Phase 3 clinical trials for moderate-to-severe pain following abdominal surgery, leveraging Lekuang Huilin's commercial expertise and sales network in anesthetic and analgesic products.